Rochette L, Ribuot C, Belichard P, Bril A, Devissaguet M
Clin Exp Hypertens A. 1987;9(2-3):365-8. doi: 10.3109/10641968709164198.
The purpose of the present study was to evaluate the effects of two CEI: captopril and perindopril on reperfusion arrhythmias and noradrenaline 3H (NA3H) release in the isolated rat heart on arrhythmias in pentobarbitone anaesthetized rats subject to left coronary artery ligation. In vitro, in control preparations, reperfusion after 10 min of local ischemia produced by coronary ligation was accompanied by a sudden release of NA3H in coronary flow and long lasting ventricular arrhythmias. Reperfusion arrhythmias were prevented by perfusion medium containing a high dose of CEI and CEI did not change the patterns of NA3H release. In vivo, mortality due to ventricular fibrillation was significantly reduced in rats pretreated with captopril or perindopril 15 min prior to coronary ligation. CEI reduced the severity of ventricular tachycardia (VT) and fibrillation (VF).
本研究的目的是评估两种血管紧张素转换酶抑制剂（CEI）：卡托普利和培哚普利对离体大鼠心脏再灌注心律失常以及去甲肾上腺素3H（NA3H）释放的影响，以及对戊巴比妥麻醉下接受左冠状动脉结扎的大鼠心律失常的影响。在体外，在对照制剂中，冠状动脉结扎导致局部缺血10分钟后的再灌注伴随着冠状动脉血流中NA3H的突然释放和持续的室性心律失常。含高剂量CEI的灌注培养基可预防再灌注心律失常，且CEI不会改变NA3H的释放模式。在体内，在冠状动脉结扎前15分钟用卡托普利或培哚普利预处理的大鼠，因心室颤动导致的死亡率显著降低。CEI降低了室性心动过速（VT）和心室颤动（VF）的严重程度。
